TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-000403
Abstract: Background FOLFOXIRI plus bevacizumab is considered a standard option in the upfront treatment of clinically selected patients with metastatic colorectal cancer irrespective of RAS and BRAF molecular status. The randomised MACBETH and VOLFI studies showed… read more here.
Keywords: metastatic colorectal; braf wild; colorectal cancer; plus panitumumab ... See more keywords
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco-24-01710
Abstract: PURPOSE ERBB2 overexpression/amplification in RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC; human epidermal growth factor receptor 2 [HER2]-positive mCRC) appears to be associated with limited benefit from anti-EGFR antibodies and promising responses to dual-HER2 inhibition;… read more here.
Keywords: her2; ras braf; her2 positive; gcn ... See more keywords
Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.12007
Abstract: 12007Background: CRICKET (NCT02296203) was designed to investigate the activity of the rechallenge with cet and iri as 3rd-line treatment in RAS/BRAF wild-type mCRC pts with acquired resistance to ... read more here.
Keywords: braf wild; pts acquired; cet; ras braf ... See more keywords
Network meta-analysis and cost-effectiveness analysis comparing Cetuximab-β and Cetuximab for Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2025.1568385
Abstract: Background The escalating economic burden of metastatic colorectal cancer (mCRC) in China necessitates cost-effective first-line treatments. Cetuximab-β, a newer version of Cetuximab, is approved for first-line RAS/BRAF wild-type mCRC. This study evaluates the cost-effectiveness of… read more here.
Keywords: analysis; ras braf; braf wild; cost effectiveness ... See more keywords
Hashimoto’s Thyroiditis: A Protective Factor against Recurrence in BRAF-Wild Type Differentiated Thyroid Carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15082371
Abstract: Simple Summary Hashimoto’s thyroiditis and BRAF-mutation are protective and risk factors for thyroid cancer aggressiveness, respectively. We assessed the influence of Hashimoto’s thyroiditis and its influence on recurrence in patients with BRAF-wild type and BRAF-mutant… read more here.
Keywords: braf; protective factor; recurrence; braf wild ... See more keywords